Clinical and molecular diagnosis of pathologic complete response in rectal cancer: an update

Corey Timmerman, Luis R. Taveras, Sergio Huerta

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Introduction: The standard of care for locally advanced rectal cancer includes neoadjuvant chemoradiation with subsequent total mesorectal excision. This approach has shown various degrees of response to neoadjuvant chemoradiation (ranging from complete response to further tumor growth), which have substantial prognostic and therapeutic implications. A total regression of the tumor is a predictor of superior oncologic outcomes compared with partial responders and non-responders. Further, this concept has opened the possibility of nonoperative strategies for complete responders and explains the widespread research interest in finding clinical, radiographic, pathologic, and biochemical parameters that allow for identification of these patients. Areas covered: The present review evaluates the most recent efforts in the literature to identify predictors of patients likely to achieve a complete response following neoadjuvant treatment for the management of rectal cancer. This includes clinical predictors of pathologic complete response such as tumor location, size, and stage, molecular predictors such as tumor biology and microRNA, serum biomarkers such as carcinoembryogenic antigen and nomograms. Expert commentary: There has been significant progress in our ability to predict pathological complete response. However, more high-quality research is still needed to use this concept to confidently dictate clinical management.

Original languageEnglish (US)
Pages (from-to)887-896
Number of pages10
JournalExpert Review of Molecular Diagnostics
Volume18
Issue number10
DOIs
StatePublished - Oct 3 2018

Fingerprint

Rectal Neoplasms
Neoplasms
Nomograms
Neoadjuvant Therapy
Standard of Care
MicroRNAs
Research
Biomarkers
Antigens
Growth
Serum
Therapeutics

Keywords

  • clinical complete response
  • Neoadjuvant chemotherapy
  • pathologic complete response
  • rectal cancer
  • tumor regression grade

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Clinical and molecular diagnosis of pathologic complete response in rectal cancer : an update. / Timmerman, Corey; Taveras, Luis R.; Huerta, Sergio.

In: Expert Review of Molecular Diagnostics, Vol. 18, No. 10, 03.10.2018, p. 887-896.

Research output: Contribution to journalReview article

@article{b4e8514e7df74a62ba2f0aa3cc1ee562,
title = "Clinical and molecular diagnosis of pathologic complete response in rectal cancer: an update",
abstract = "Introduction: The standard of care for locally advanced rectal cancer includes neoadjuvant chemoradiation with subsequent total mesorectal excision. This approach has shown various degrees of response to neoadjuvant chemoradiation (ranging from complete response to further tumor growth), which have substantial prognostic and therapeutic implications. A total regression of the tumor is a predictor of superior oncologic outcomes compared with partial responders and non-responders. Further, this concept has opened the possibility of nonoperative strategies for complete responders and explains the widespread research interest in finding clinical, radiographic, pathologic, and biochemical parameters that allow for identification of these patients. Areas covered: The present review evaluates the most recent efforts in the literature to identify predictors of patients likely to achieve a complete response following neoadjuvant treatment for the management of rectal cancer. This includes clinical predictors of pathologic complete response such as tumor location, size, and stage, molecular predictors such as tumor biology and microRNA, serum biomarkers such as carcinoembryogenic antigen and nomograms. Expert commentary: There has been significant progress in our ability to predict pathological complete response. However, more high-quality research is still needed to use this concept to confidently dictate clinical management.",
keywords = "clinical complete response, Neoadjuvant chemotherapy, pathologic complete response, rectal cancer, tumor regression grade",
author = "Corey Timmerman and Taveras, {Luis R.} and Sergio Huerta",
year = "2018",
month = "10",
day = "3",
doi = "10.1080/14737159.2018.1514258",
language = "English (US)",
volume = "18",
pages = "887--896",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Clinical and molecular diagnosis of pathologic complete response in rectal cancer

T2 - an update

AU - Timmerman, Corey

AU - Taveras, Luis R.

AU - Huerta, Sergio

PY - 2018/10/3

Y1 - 2018/10/3

N2 - Introduction: The standard of care for locally advanced rectal cancer includes neoadjuvant chemoradiation with subsequent total mesorectal excision. This approach has shown various degrees of response to neoadjuvant chemoradiation (ranging from complete response to further tumor growth), which have substantial prognostic and therapeutic implications. A total regression of the tumor is a predictor of superior oncologic outcomes compared with partial responders and non-responders. Further, this concept has opened the possibility of nonoperative strategies for complete responders and explains the widespread research interest in finding clinical, radiographic, pathologic, and biochemical parameters that allow for identification of these patients. Areas covered: The present review evaluates the most recent efforts in the literature to identify predictors of patients likely to achieve a complete response following neoadjuvant treatment for the management of rectal cancer. This includes clinical predictors of pathologic complete response such as tumor location, size, and stage, molecular predictors such as tumor biology and microRNA, serum biomarkers such as carcinoembryogenic antigen and nomograms. Expert commentary: There has been significant progress in our ability to predict pathological complete response. However, more high-quality research is still needed to use this concept to confidently dictate clinical management.

AB - Introduction: The standard of care for locally advanced rectal cancer includes neoadjuvant chemoradiation with subsequent total mesorectal excision. This approach has shown various degrees of response to neoadjuvant chemoradiation (ranging from complete response to further tumor growth), which have substantial prognostic and therapeutic implications. A total regression of the tumor is a predictor of superior oncologic outcomes compared with partial responders and non-responders. Further, this concept has opened the possibility of nonoperative strategies for complete responders and explains the widespread research interest in finding clinical, radiographic, pathologic, and biochemical parameters that allow for identification of these patients. Areas covered: The present review evaluates the most recent efforts in the literature to identify predictors of patients likely to achieve a complete response following neoadjuvant treatment for the management of rectal cancer. This includes clinical predictors of pathologic complete response such as tumor location, size, and stage, molecular predictors such as tumor biology and microRNA, serum biomarkers such as carcinoembryogenic antigen and nomograms. Expert commentary: There has been significant progress in our ability to predict pathological complete response. However, more high-quality research is still needed to use this concept to confidently dictate clinical management.

KW - clinical complete response

KW - Neoadjuvant chemotherapy

KW - pathologic complete response

KW - rectal cancer

KW - tumor regression grade

UR - http://www.scopus.com/inward/record.url?scp=85054369005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054369005&partnerID=8YFLogxK

U2 - 10.1080/14737159.2018.1514258

DO - 10.1080/14737159.2018.1514258

M3 - Review article

C2 - 30124091

AN - SCOPUS:85054369005

VL - 18

SP - 887

EP - 896

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 10

ER -